Persistent vulvovaginal candidiasis: systemic treatment with oral fluconazole.
52 patients affected by persistent vulvovaginal candidiasis underwent systemic therapy with oral Fluconazole at a dose of 150 mg once a week for 3 weeks. 31 (59.61%) patients were cured at the first control after therapy. Of the remaining 21 patients, 4 (7.69%) were lost at follow-up and 17 (32.69%) underwent a second cycle of systemic therapy with complete recovery confirmed at the further controls. The overall percentage of recoveries was equal to 92.30%. The results suggest that Fluconazole is very effective in mycotic vulvovaginitis with irrelevant side effects.
Frega
A
A
II Clinics of Obstetrics and Gynecology, University of Rome, La Sapienza, Italy.
Gallo
G
G
Di Renzi
F
F
Stolfi
G
G
Stentella
P
P
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D016896:Treatment Outcome
D015725:Fluconazole